Quick Answer
Pyxis Oncology, Inc. reported Cash and Equivalents of $15.42 million for fiscal year 2025.
Pyxis Oncology, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $15.42M | -20.8% |
| 2024 | $19.47M | +101.5% |
| 2023 | $9.66M | -94.6% |
| 2022 | $179.29M | -34.7% |
| 2021 | $274.74M | +3300.2% |
| 2020 | $8.08M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.92M | -26.0% | -16.9% |
| June 30, 2025 | $10.73M | -57.2% | -15.9% |
| March 31, 2025 | $12.76M | -54.4% | -34.5% |
| December 31, 2024 | $19.47M | +101.5% | +61.5% |
| September 30, 2024 | $12.06M | -18.1% | -51.9% |
| June 30, 2024 | $25.07M | -3.2% | -10.3% |
| March 31, 2024 | $27.97M | -47.3% | +189.4% |
| December 31, 2023 | $9.66M | -94.6% | -34.3% |
- Pyxis Oncology, Inc. showed a decrease of -20.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Pyxis Oncology, Inc.’s cash and equivalents has grown by 90.9% (from $8.08 million to $15.42 million).
- The most recent figure is from Pyxis Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: